索拉非尼联合放射治疗肝癌研究进展

Research progress on sorafenib combined with radiation in treatment of hepatocellular carcinoma

索拉非尼是多靶点激酶抑制剂,通过抗增殖和抗血管形成作用抑制肿瘤细胞生长和血管形成,其作用机制是靶向抑制丝裂原活化蛋白激酶(Ras/Raf/MAPK)、血管内皮生长因子/血管内皮生长因子受体(VEGF/VEGFR)和核因子κB(NF-κB)等信号传导通路,而这些信号通路在放射时被激活,在肿瘤发生发展过程中起着重要的作用。研究显示,索拉非尼联合放射治疗原发性肝癌有协同效应,但联合方案的基础和临床研究有待进一步探索。

Sorafenib is a multikinase inhibitor that acts by inhibiting tumor growth and disrupting tumor mi- erovaseulature through antiproliferative and anti-angiogenie effects. It exerts these effects via inhibition of multiple tar- gets including Ras/Raf/MAPK, VEGF/VEGFR and NF-KB signal pathways, which can be induced by radiation. Sorafenib combined with radiation in hepatoeellular carcinoma treatment has been explored and shown synergistic re- sults. The basic and clinical studies on the effects and roechanisms of the combining modality should be further inves- tigated.